4120.TWO Orient Europharma Co Ltd
- Market cap
- TWD 3.67B
- P/E
- -
- P/B
- 0.71x
- ROE
- -8.0%
- Dividend yield
- 2.76%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4120.TWO undervalued?
Graham numberThe Graham number of Orient Europharma Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orient Europharma Co Ltd fundamental analysis
No fundamental analysis for Orient Europharma Co Ltd yet.
Orient Europharma Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids,…
Full company profileOrient Europharma Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orient Europharma Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.23B | 5.23B | 5.51B | 6.09B | 5.38B | 4.77B | 4.73B | 4.59B | 4.39B | 4.60B | 4.68B |
| Gross Profit | 2.41B | 2.47B | 2.58B | 2.81B | 2.42B | 2.15B | 2.03B | 2.15B | 2.07B | 2.24B | 2.31B |
| Operating Income | 451M | 435M | 357M | 331M | 117M | -98.1M | -150M | 72.1M | 13.3M | -299M | -193M |
| EBITDA | - | 646M | 490M | 572M | 477M | 314M | -64.3M | 579M | 184M | -1.18M | 167M |
| Net Income | 470M | 459M | 247M | 248M | 199M | 120M | -311M | 144M | -284M | -567M | -416M |
| EPS | - | 5.29 | 2.84 | 2.86 | 2.30 | 1.39 | -3.58 | 1.66 | -3.27 | -6.54 | -4.80 |
| Balance Sheet | |||||||||||
| Total Assets | 6.49B | 6.65B | 7.24B | 7.87B | 8.16B | 9.40B | 10.4B | 10.8B | 11.6B | 12.2B | 11.8B |
| Total Liabilities | 2.57B | 2.56B | 3.10B | 4.06B | 4.25B | 5.95B | 6.99B | 6.65B | 5.75B | 4.85B | 5.41B |
| Shareholders' Equity | 3.14B | 3.27B | 3.28B | 3.19B | 3.21B | 2.94B | 2.93B | 3.51B | 5.16B | 6.29B | 5.23B |
| Cash & Short-term Investments | 1.34B | 1.30B | 1.75B | 1.75B | 2.12B | 1.96B | 1.80B | 1.74B | 1.44B | 1.95B | 1.55B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 111M | 601M | 231M | 227M | 609M | 77.6M | -219M | 64.7M | -121M | -292M | -579M |
| Capital Expenditure | 225M | 368M | 202M | 125M | 233M | 1.56B | 639M | 101M | 100M | 189M | 321M |
| Free Cash Flow | - | 364M | 26.9M | 48.7M | 373M | -1.49B | -860M | -36.0M | -221M | -481M | -900M |
| Ratios | |||||||||||
| ROE | 14.9% | 14.0% | 7.5% | 7.8% | 6.2% | 4.1% | -10.6% | 4.1% | -5.5% | -9.0% | -8.0% |
| ROA | 7.2% | 6.9% | 3.4% | 3.1% | 2.4% | 1.3% | -3.0% | 1.3% | -2.5% | -4.6% | -3.5% |
| Net Profit Margin | 9.0% | 8.8% | 4.5% | 4.1% | 3.7% | 2.5% | -6.6% | 3.1% | -6.5% | -12.3% | -8.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Orient Europharma Co Ltd dividends
- Dividend yield
- 2.76%
- Forward dividend
- 4.00 TWD
- Payout ratio
- -
- Ex-dividend date
- Jul 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 101M | 1.16 | - |
| 2024 | TWD 101M | 1.16 | - |
| 2023 | TWD 15.6M | 0.18 | 10.8% |
| 2022 | TWD 73.7M | 0.85 | - |
| 2021 | TWD 130M | 1.50 | 108.3% |
| 2020 | TWD 156M | 1.80 | 78.3% |
| 2019 | TWD 156M | 1.80 | 63.0% |
| 2018 | TWD 217M | 2.50 | 87.9% |
| 2017 | TWD 156M | 1.80 | 34.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1160:1000 on Jul 28, 2010.
Who owns Orient Europharma Co Ltd
- Insiders 67.63%
- Institutions 0.23%
- Public & others 32.14%
- Shares outstanding 86.7M
- Free float 31.5M
Orient Europharma Co Ltd company profile
- Company name
- Orient Europharma Co Ltd
- Ticker
- 4120.TWO
- ISIN
- TW0004120001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No. 128, Chengde Rd., Taipei, Taiwan, 112052
- Phone
- 886 2 2755 4881
- Website
- oepgroup.com
About Orient Europharma Co Ltd
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include weight management, andrology, cardiovascular, respiratory, neurology, cardiovascular, metabolism, obstetrics and gynecology, antibiotic, immunology, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk under the Karihome brand name; and healthcare supplements for liquid nutrition, regular blood lipids, L-arginines, agile movements, and improved sleep qualities under the Nutrifuel brand name. In addition, the company offers dermo and cosmetic products under the Cumlaude Labs, AGLabs, Bio-Oil, and ISISPHARMAs brand names. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trial. Orient EuroPharma Co., Ltd. was incorporated in 1982 and is based in Taipei, Taiwan.
Orient Europharma Co Ltd management
4- Mr. Meng-Lin TsaiGeneral Manager
- Pin-Chieh WangFinancial Officer & Accounting Officer
- Liann LaiDirector of Human Resources & Administrative Division
- Ming-Hsia HungChief Audit Officer